Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 7/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 6/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771385 | 0.89 | MKNK1 (0.44) | MKNK1MKNK2CHEK2FYNMAP4K4 | |
| SCHEMBL4029897 | 0.85 | LRRK2 (0.44) | MKNK1MKNK2CHEK2ERN1 | |
| SCHEMBL13404775 | 0.81 | JAK2 (0.41) | MAP4K4IKBKB | |
| SCHEMBL4024297 | 0.81 | HPGD (0.45) | — | |
| SCHEMBL751010 | 0.81 | MKNK1 (0.42) | MKNK1MKNK2CHEK2MAP4K4 | |
| SCHEMBL3274060 | 0.80 | IKBKB (0.35) | MKNK1MKNK2FYNMAP4K4IKBKB | |
| SCHEMBL3583617 | 0.80 | SMN1; SMN2 (0.38) | MAP4K4 | |
| SCHEMBL3273740 | 0.80 | IDO1 (0.44) | MKNK1MKNK2MAP4K4IKBKB | |
| SCHEMBL4436864 | 0.79 | MKNK1 (0.47) | MKNK1MKNK2CHEK2FYNIKBKB | |
| SCHEMBL4024291 | 0.78 | CHEK2 (0.31) | CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537075-B1 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH AS (DK) | 2009-07-01 | — | — | EP | disclosed |
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | NEUROSEARCH A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1537075-A2 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004022529-A2 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | KIT, ORAI1, CACNA1C | MKNK1 4273/4885MKNK2 4470/4885CHEK2 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.